Literature DB >> 10518034

Hormone-activated nuclear receptors inhibit the stimulation of the JNK and ERK signalling pathways in endothelial cells.

M V González1, J M González-Sancho, C Caelles, A Munoz, B Jiménez.   

Abstract

Glucocorticoid hormones, retinoids, and vitamin D3 display anti-angiogenic activity in tumor-bearing animals. However, despite their in vivo effect on the tumor vasculature little is known about their mechanism of action. Here we show that the synthetic glucocorticoid dexamethasone (Dex) and retinoic acid (RA) inhibit the activation of c-Jun N-terminal kinase (JNK) and extracellular-regulated kinase (ERK) signalling pathways by the pro-angiogenic agents tumor necrosis factor and vascular endothelial growth factor in endothelial cells. In contrast, Dex and RA failed to inhibit the activation of the p38 mitogen-activated protein kinase cascade. As a number of pro-angiogenic factors activate AP-1 transcription factor via the JNK and ERK pathways, our results suggest that the antagonism with AP-1 may underlie at least partially the anti-angiogenic effect of glucocorticoids and retinoids.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10518034     DOI: 10.1016/s0014-5793(99)01257-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

Review 1.  Pathogen recognition and inflammatory signaling in innate immune defenses.

Authors:  Trine H Mogensen
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

2.  Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38.

Authors:  M Lasa; M Brook; J Saklatvala; A R Clark
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

3.  Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1.

Authors:  O Kassel; A Sancono; J Krätzschmar; B Kreft; M Stassen; A C Cato
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

4.  Specific activation of the glucocorticoid receptor and modulation of signal transduction pathways in human lens epithelial cells.

Authors:  Vanita Gupta; Niranjan Awasthi; B J Wagner
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-04       Impact factor: 4.799

5.  Expression of glucocorticoid-induced leucine zipper (GILZ) in cardiomyocytes.

Authors:  David C Aguilar; Josh Strom; Beibei Xu; Kyle Kappeler; Qin M Chen
Journal:  Cardiovasc Toxicol       Date:  2013-06       Impact factor: 3.231

6.  Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation.

Authors:  Petra Isabel Lorenzo; Fahri Saatcioglu
Journal:  Neoplasia       Date:  2008-05       Impact factor: 5.715

7.  The stimulus-dependent co-localization of serum- and glucocorticoid-regulated protein kinase (Sgk) and Erk/MAPK in mammary tumor cells involves the mutual interaction with the importin-alpha nuclear import protein.

Authors:  Patricia Buse; Anita C Maiyar; Kim L Failor; Susan Tran; Meredith L L Leong; Gary L Firestone
Journal:  Exp Cell Res       Date:  2007-07-19       Impact factor: 3.905

8.  Mechanisms of dexamethasone-mediated inhibition of Toll-like receptor signaling induced by Neisseria meningitidis and Streptococcus pneumoniae.

Authors:  Trine H Mogensen; Randi S Berg; Søren R Paludan; Lars Østergaard
Journal:  Infect Immun       Date:  2007-10-15       Impact factor: 3.441

9.  Glucocorticoids antagonize AP-1 by inhibiting the Activation/phosphorylation of JNK without affecting its subcellular distribution.

Authors:  M V González; B Jiménez; M T Berciano; J M González-Sancho; C Caelles; M Lafarga; A Muñoz
Journal:  J Cell Biol       Date:  2000-09-04       Impact factor: 10.539

10.  Glucocorticoids synergize with IL-1beta to induce TLR2 expression via MAP Kinase Phosphatase-1-dependent dual Inhibition of MAPK JNK and p38 in epithelial cells.

Authors:  Akihiro Sakai; Jiahuai Han; Andrew C B Cato; Shizuo Akira; Jian-Dong Li
Journal:  BMC Mol Biol       Date:  2004-05-04       Impact factor: 2.946

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.